

FOR IMMEDIATE RELEASE

WILMINGTON, NC October 1, 2012 – (Eqalix, Inc), today announced that Joseph P. Connell, CEO will be presenting at the 2012 Stem Cell Meeting on the Mesa's Investor and Partnering Forum—the regenerative medicine industry's premier business development and partnering meeting. The Investor and Partnering Forum is being organized by the Alliance for Regenerative Medicine (ARM) and the California Institute for Regenerative Medicine to profile the industry's most exciting technologies. Thirty-five companies and organizations will be presented over the course of 2 days, ranging from translational research centers to emerging-growth biotech companies, as well as established, publicly traded industry leaders.

The following are specific details regarding *Eqalix's* presentation at the conference:

Date: October 29th, 2012

Time: 5:15pm PST

Location: Sanford Consortium for Regenerative Medicine Building
Auditorium, Second Floor Terrace
2880 Torrey Pines Scenic Drive, La Jolla, California

The Investor and Partnering Forum was created in 2011 to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. It will be held immediately prior to the Stem Cell Meeting on the Mesa's Scientific Symposium organized by the Sanford Consortium, and the combined meetings are expected to attract over 800 attendees from around the globe. The company presentations will be recorded by ARM and will be made available on ARM's website shortly after the event. To learn more or to register for the 2012 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit www.stemcellmeetingonthemesa.com. Registration is required.

About Eqalix:

Eqalix, Inc. is an emerging biotechnology development company with a goal of enhancing the quality of life of consumers and patients by providing novel nano-materials for the repair and regeneration of diseased, traumatized, and aging tissues. Their innovative technologies are intended to revolutionize the unmet needs in multiple commercial and therapeutic applications in the Regenerative Medicine space. Connell says: "Our technologies move the bar higher and intend to replicate the function of damaged, diseased or aging tissues by providing "implants" or scaffolds that are non-immunogenic, bio-compatible, and are intended to restore the features and function of the damaged tissue by using the body's own repair mechanisms that will either replace the implant with its own tissue, or transform the implant so it is seen by the body as a natural extension of it.."

Eqalix has received exclusive commercial licensing from three prominent institutions (University of Pennsylvania, Drexel University and Children's Hospital of Philadelphia) for several groundbreaking technologies to be developed in the fields of aesthetic dermatology, the consumer market for wound treatments, acute and chronic wounds requiring skin replacement, vascular replacements, and to repair traumatic damage to peripheral nerves.

Using these technologies, Eqalix plans to develop and commercialize:

- (a) plant-protein based nano-fiber scaffold for use in aesthetic dermatology and wound healing markets

(b) small- diameter hybrid vessels that foster the creation of a functional endothelium after implantations

(c) 3-Dimensional tissue scaffolds with adjustable properties for organ and tissue replacement and repair

For Inquiries Contact:

Joseph P. Connell

President & CEO

Eqalix, Inc.

1900 Campus Commons Drive; Suite 100

Reston, VA 20191

910-233-0806